Patents by Inventor Natarajan Sethuraman

Natarajan Sethuraman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250051393
    Abstract: Compounds that include a cyclic cell penetrating peptide and a therapeutic moiety modulates Interferon Regulatory Factor-5 (IRF-5) activity in an immune cell. The therapeutic moiety is a therapeutic protein, a small molecule, or an antisense compound. Methods include administering the compound to cells or subjects to modulate IRF-5 activity. Methods include treating diseases associated with IRF-5 using the compounds.
    Type: Application
    Filed: May 9, 2022
    Publication date: February 13, 2025
    Inventors: Ziqing QIAN, Natarajan SETHURAMAN, Mahboubeh KHEIRABADI, Haoming LIU, Xiulong SHEN, Xiang LI
  • Publication number: 20250051780
    Abstract: Compounds include at least one cyclic cell penetrating peptide (cCPP) conjugated to an antisense compound (AC). The AC modulates splicing of an RNA transcript. For example, the AC induces exon skipping. Exon skipping can result in down-regulation of expression or activity of a protein. Exon skipping may cause a frameshift in a resulting mRNA. The frameshift may result in a premature termination codon. The frameshift may result in nonsense mediated decay.
    Type: Application
    Filed: May 9, 2022
    Publication date: February 13, 2025
    Inventors: Ziqing QIAN, Natarajan SETHURAMAN, Xiulong SHEN, Haoming LIU, Xiang LI
  • Publication number: 20240417429
    Abstract: Described herein in various embodiments are compositions comprising (a) a cell penetrating peptide (CPP) sequence; and (b) an antisense compound, wherein the antisense compound targets exon 45 of the DMD gene.
    Type: Application
    Filed: August 30, 2022
    Publication date: December 19, 2024
    Inventors: Xiang Li, Ziqing Qian, Mahboubeh Kheirabadi, Ming Zhou, Mahsweta Girgenrath, Nelsa Estrella, Suresh Peddigari, Anushree Pathak, Natarajan Sethuraman, Wenlong Lian, Nanjun Liu
  • Patent number: 12084651
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: September 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Publication number: 20240247259
    Abstract: Compounds that include a cyclic cell penetrating peptide and a therapeutic moiety that modulates polyadenylation of a gene transcript. The therapeutic moiety may be an antisense compound (AC) that binds a target gene transcript. The AC may bind to at least a portion of a polyadenylation signal element (PSE) or may bind in sufficiently close proximity to the PSE to modulate polyadenylation of the target gene transcript. Methods include administering the aforementioned compounds to cells or subjects to modulate diseases or conditions.
    Type: Application
    Filed: May 9, 2022
    Publication date: July 25, 2024
    Inventors: Xiulong SHEN, Xiang LI, Ziqing QIAN, Natarajan SETHURAMAN, Haoming LIU
  • Patent number: 11987821
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: May 21, 2024
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Natarajan Sethuraman, Jason Ruth, Louis A. Tartaglia, Dehua Pei, Ziqing Qian
  • Publication number: 20230027739
    Abstract: Degradation compounds include a cyclic cell penetrating peptide (cCPP) and a degradation construct. The degradation construct includes a degradation moiety and a targeting moiety. The targeting moiety binds a target protein. When the targeting moiety is bound to the target protein, the degradation moiety mediates degradation of the target protein. The cCPP facilitates transfer of the degradation construct into a cell. The degradation compound may further include an exocyclic peptide to enhance endosomal escape of the compound or degradation construct once inside the cell.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Natarajan SETHURAMAN, Patrick DOUGHERTY, Byung-Kwon CHOI, Nicholas Emerson LONG, Ziqing QIAN
  • Publication number: 20230020092
    Abstract: Provided herein are compounds comprising cyclic cell penetrating peptides and antisense compounds. Also provided herein are methods of modulating splicing, inhibiting or regulating translation, mediating degradation, blocking expansions of nucleotide repeats, and treating disease using the aforementioned compounds.
    Type: Application
    Filed: December 21, 2020
    Publication date: January 19, 2023
    Inventors: Ziqing Qian, Xiang Li, Mahboubeh Kheirabadi, Mohanraj Dhanabal, Haoming Liu, Xiulong Shen, Kimberli Kamer, Natarajan Sethuraman
  • Publication number: 20220033787
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Application
    Filed: October 6, 2021
    Publication date: February 3, 2022
    Inventors: Natarajan SETHURAMAN, Jason RUTH, Louis A. TARTAGLIA, Dehua PEI, Ziqing QIAN
  • Patent number: 11168310
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: November 9, 2021
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Natarajan Sethuraman, Jason Ruth, Lou A. Tartaglia, Dehua Pei, Ziqing Qian
  • Publication number: 20210317441
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: June 10, 2021
    Publication date: October 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Patent number: 11046951
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Publication number: 20200354697
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Application
    Filed: March 17, 2020
    Publication date: November 12, 2020
    Inventors: Natarajan SETHURAMAN, Jason RUTH, Lou A. TARTAGLIA, Dehua PEI, Ziqing QIAN
  • Publication number: 20190055546
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: October 3, 2018
    Publication date: February 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Publication number: 20170327817
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: January 27, 2016
    Publication date: November 16, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Patent number: 9758553
    Abstract: Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal ?-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 12, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Natarajan Sethuraman, Robert C. Davidson, Terrance A. Stadheim, Stefan Wildt
  • Publication number: 20170107509
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: January 27, 2016
    Publication date: April 20, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Publication number: 20160289290
    Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1-9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(1-4)GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of NANA(1-4)Gal(1-4)GlcNAc(1-4)Man3GlcNAc2.
    Type: Application
    Filed: January 14, 2016
    Publication date: October 6, 2016
    Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
  • Patent number: 9428784
    Abstract: Methods for increasing the yield and N-glycosylation site occupancy of paucimannose or complex N-glycans of recombinant glycoproteins produced in a recombinant host cell lacking dolichyl-P-Man:Man5GlcNAc2-PP-dolichyl alpha-1,3 mannosyltransferase (Alg3p) activity are disclosed. In particular, recombinant host cells are provided that comprise a disruption of the expression of an OS-9 family gene in the host cell. These recombinant host cells may then be used for producing recombinant glycoproteins. In further embodiments, the recombinant host cells further overexpress at least one heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: August 30, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Byung-Kwon Choi, Stephen R. Hamilton, Natarajan Sethuraman
  • Publication number: 20160215061
    Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides which are useful as human or animal therapeutic agents, and which comprise increased anti-inflammatory properties and improved FcyRIIb binding.
    Type: Application
    Filed: October 3, 2014
    Publication date: July 28, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Hussam H. Shaheen, Andy Stadheim, Natarajan Sethuraman